Alnylam Pharmaceuticals
ALNY
473 hedge funds and large institutions have $22.5B invested in Alnylam Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 165 increasing their positions, 154 reducing their positions, and 56 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 154
0% less funds holding
Funds holding: 475 → 473 (-2)
1.1% less ownership
Funds ownership: 96.33% → 95.23% (-1.1%)
11% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 56
20% less capital inflows, than outflows
Capital inflows: $765M | Capital outflows: $961M
26% less call options, than puts
Call options by funds: $119M | Put options by funds: $162M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$129M |
| 2 |
Morgan Stanley
New York
|
+$129M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$83.7M |
| 4 |
Bank of New York Mellon
New York
|
+$43.9M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$162M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$134M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$83M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$50.4M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$49M |
ALNY Hedge Fund Activity: Q2 2023 in Review
473 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2023, worth a combined $22.5B — down 6% from $24B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of ALNY and 50 opened new positions — a net loss of 6 holders — while 154 trimmed existing stakes and 165 added.
The largest buyer was Capital International Investors, adding an estimated $129M. The largest seller was Norges Bank, cutting an estimated $162M.
- 473 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2023, down from 475 in Q1 2023.
- Funds reported $22.5B of Alnylam Pharmaceuticals stock for Q2 2023, down 6% quarter-over-quarter.
- 50 funds opened new Alnylam Pharmaceuticals positions in Q2 2023 and 56 closed out, a net change of -6 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2023 was Capital International Investors, an estimated $129M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2023 was Norges Bank, an estimated $162M sold.
Based on aggregated 13F filings for Q2 2023.